The Leukemia & Lymphoma Society (LLS) and Forma Therapeutics have entered into a collaboration to discover and develop small molecule compounds for the treatment of B cell lymphoma.
The lymphoma target Bcl-6 is a transcriptional repressor that down regulates genes responsible for the function of normal and tumour cells.
The collaboration aims at blocking Bcl-6 interaction with a protein co-repressor called SMRT.
B lymphocyte cells, which are a key component of the immune system, can become cancerous and lead to diseases such as non-Hodgkin's lymphoma.
LLS has committed funding support to this collaboration as part of its Therapy Acceleration Program and the collaboration is an expansion of the partnership entered by the organisations in July 2009.